Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.
Adolescent
Adult
Bone Marrow Diseases
/ genetics
Child
Child, Preschool
Clonal Hematopoiesis
/ genetics
Eukaryotic Initiation Factors
/ genetics
Female
Humans
Infant
Male
Middle Aged
Mutation
Ribosomes
/ genetics
Shwachman-Diamond Syndrome
/ genetics
Tumor Suppressor Protein p53
/ genetics
Young Adult
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
26 02 2021
26 02 2021
Historique:
received:
29
07
2020
accepted:
29
01
2021
entrez:
27
2
2021
pubmed:
28
2
2021
medline:
16
3
2021
Statut:
epublish
Résumé
To understand the mechanisms that mediate germline genetic leukemia predisposition, we studied the inherited ribosomopathy Shwachman-Diamond syndrome (SDS), a bone marrow failure disorder with high risk of myeloid malignancies at an early age. To define the mechanistic basis of clonal hematopoiesis in SDS, we investigate somatic mutations acquired by patients with SDS followed longitudinally. Here we report that multiple independent somatic hematopoietic clones arise early in life, most commonly harboring heterozygous mutations in EIF6 or TP53. We show that germline SBDS deficiency establishes a fitness constraint that drives selection of somatic clones via two distinct mechanisms with different clinical consequences. EIF6 inactivation mediates a compensatory pathway with limited leukemic potential by ameliorating the underlying SDS ribosome defect and enhancing clone fitness. TP53 mutations define a maladaptive pathway with enhanced leukemic potential by inactivating tumor suppressor checkpoints without correcting the ribosome defect. Subsequent development of leukemia was associated with acquisition of biallelic TP53 alterations. These results mechanistically link leukemia predisposition to germline genetic constraints on cellular fitness, and provide a rational framework for clinical surveillance strategies.
Identifiants
pubmed: 33637765
doi: 10.1038/s41467-021-21588-4
pii: 10.1038/s41467-021-21588-4
pmc: PMC7910481
doi:
Substances chimiques
EIF6 protein, human
0
Eukaryotic Initiation Factors
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1334Subventions
Organisme : NCI NIH HHS
ID : K08 CA204734
Pays : United States
Organisme : NIDDK NIH HHS
ID : RC2 DK122533
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA217835
Pays : United States
Organisme : NIDDK NIH HHS
ID : R24 DK099808
Pays : United States
Références
Blood. 2005 Aug 15;106(4):1253-8
pubmed: 15860664
Cell Rep. 2018 Nov 27;25(9):2308-2316.e4
pubmed: 30485801
Adv Biol Regul. 2018 Jan;67:109-127
pubmed: 28942353
Science. 2019 Aug 9;365(6453):599-604
pubmed: 31395785
J Mol Biol. 2011 Jan 14;405(2):607-18
pubmed: 21073878
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Blood. 2001 May 15;97(10):3011-6
pubmed: 11342425
Gastroenterology. 2012 Aug;143(2):481-92
pubmed: 22510201
Proteins. 2009;77 Suppl 9:89-99
pubmed: 19701941
Curr Protoc Hum Genet. 2008 Apr;Chapter 10:Unit 10.11
pubmed: 18428421
Haematologica. 2012 Sep;97(9):1312-9
pubmed: 22491737
Nucleic Acids Res. 2016 Jul 8;44(W1):W344-50
pubmed: 27166375
Ann N Y Acad Sci. 2011 Dec;1242:40-55
pubmed: 22191555
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
J Clin Invest. 2008 Apr;118(4):1511-8
pubmed: 18324336
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
Nature. 2003 Dec 4;426(6966):579-84
pubmed: 14654845
In Vitro Cell Dev Biol Anim. 2011 Feb;47(2):132-8
pubmed: 21082278
Nature. 2012 Nov 1;491(7422):56-65
pubmed: 23128226
Blood. 2015 Feb 26;125(9):1367-76
pubmed: 25550361
Blood. 2011 Oct 20;118(16):4305-12
pubmed: 21803848
J Clin Oncol. 2017 Mar 20;35(9):1018-1028
pubmed: 28297620
Biomaterials. 2017 Sep;139:102-115
pubmed: 28599149
Arch Pathol Lab Med. 2002 Apr;126(4):452-5
pubmed: 11900571
Eur J Hum Genet. 1997 May-Jun;5(3):137-48
pubmed: 9272737
Nat Biotechnol. 2012 May;30(5):413-21
pubmed: 22544022
Lancet Haematol. 2020 Mar;7(3):e238-e246
pubmed: 31879230
Nat Genet. 2012 Oct;44(10):1111-6
pubmed: 22941189
PLoS Comput Biol. 2020 Sep 21;16(9):e1008103
pubmed: 32956350
Mol Ther. 2015 Sep;23(9):1465-74
pubmed: 26080908
N Engl J Med. 2017 Feb 9;376(6):536-547
pubmed: 28177873
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2532-7
pubmed: 11226273
Br J Haematol. 2012 May;157(4):503-5
pubmed: 22295858
Nat Methods. 2011 Jun 26;8(8):659-61
pubmed: 21706014
Exp Hematol. 2002 Jul;30(7):659-69
pubmed: 12135662
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Biochim Biophys Acta. 2014 Jun;1842(6):817-30
pubmed: 24514102
Nat Genet. 2003 Jan;33(1):97-101
pubmed: 12496757
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Nature. 2009 Apr 9;458(7239):719-24
pubmed: 19360079
Br J Haematol. 2006 Mar;132(5):630-5
pubmed: 16445838
Hematol Oncol Clin North Am. 2018 Aug;32(4):687-700
pubmed: 30047420
J Biol Chem. 2010 May 14;285(20):14848-51
pubmed: 20356839
Cancer Cell. 2011 Jun 14;19(6):765-75
pubmed: 21665150
J Phys Chem B. 2018 May 31;122(21):5389-5399
pubmed: 29401388
Nat Struct Biol. 2000 Dec;7(12):1156-64
pubmed: 11101899
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Leukemia. 2014 Jan;28(1):34-43
pubmed: 23979521
Nat Genet. 2007 Apr;39(4):486-95
pubmed: 17353896
Blood. 2010 Apr 22;115(16):3196-205
pubmed: 20194897
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Nat Med. 2020 Oct;26(10):1549-1556
pubmed: 32747829
Blood. 2018 Jan 25;131(4):408-416
pubmed: 29092827
Nat Struct Mol Biol. 2015 Nov;22(11):914-9
pubmed: 26479198
Structure. 2013 Oct 8;21(10):1735-42
pubmed: 24035711
Nat Methods. 2011 Dec 04;9(2):179-81
pubmed: 22138821
Blood. 2007 Sep 1;110(5):1458-65
pubmed: 17475909
Blood. 2016 Jul 21;128(3):462-463
pubmed: 31659364